爪真菌症(爪白癬)(Onychomycosis (Tinea Unguium)):治療薬パイプラインレビュー

◆英語タイトル:Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2018
◆商品コード:GMDHC10618IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年7月17日
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Onychomycosis (Tinea Unguium) – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H2 2018, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 2, 2, 1 and 2 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) – Overview
Onychomycosis (Tinea Unguium) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) – Companies Involved in Therapeutics Development
Almirall SA
Blueberry Therapeutics Ltd
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Novan Inc
Viamet Pharmaceuticals Inc
Onychomycosis (Tinea Unguium) – Drug Profiles
Amphotericin B sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-0305 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HXP-124 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-607 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ME-1111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NORS-0791 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-213 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-3058 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onychomycosis (Tinea Unguium) – Dormant Projects
Onychomycosis (Tinea Unguium) – Discontinued Products
Onychomycosis (Tinea Unguium) – Product Development Milestones
Featured News & Press Releases
May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Nov 20, 2017: Moberg Pharma replaces CRO in Phase 3 studies for MOB-015
Nov 08, 2017: Moberg Pharma provides update on timeline for MOB-015
Jul 27, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
Jun 21, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases
Apr 12, 2017: Novan Reports Positive Top line Results with SB208 in Phase 2 Trial
Mar 06, 2017: Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at the American Academy of Dermatology Annual Meeting
Mar 01, 2017: Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the American Academy of Dermatology 2017 Annual Meeting
Nov 08, 2016: Hallux Announces Start of Phase 2 Clinical Trial
Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting
Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-015
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H2 2018
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H2 2018
Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2018
Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Onychomycosis (Tinea Unguium) - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[爪真菌症(爪白癬)(Onychomycosis (Tinea Unguium)):治療薬パイプラインレビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆